ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
IRVINE, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ — ChromaDex Corporation (OTC Bulletin Board: CDXC), a leader in phytochemical reference standards and related contract analysis and research services, today announced that it has entered into a global agreement with Kappa Bioscience AS (Oslo, Norway) to supply analytical reference standards, quality control methods and related analytical testing services for Vitamin K2, Menaquinone-7(MK-7) in raw materials and finished goods.
“With increasing market demand for Vitamin K2 MK-7, there will be an increase in demand for reference standards, quality control methods, research tools and analytical services,” said Frank Jaksch, CEO and co-founder of ChromaDex. “Since MK-7 is a vitamin product manufactured from different sources, it is critical that testing procedures are in place to ensure the quality and consistency of any MK-7 related ingredient or product.”
Vitamin K2 is shown to have significant importance for optimal utilization of calcium in the body related to bone and cardiovascular health. Studies indicate that the Western diet is deficient in Vitamin K2. Thus, daily supplementation is expected to be beneficial for the bone building process as well as for cardiovascular health.
“The market needs a reliable and impartial third party expert like ChromaDex to bring clarity to Vitamin K analysis,” said Egil Greve, CEO of Kappa Bioscience. “To date it has been difficult, if not impossible, to verify the label claims of Vitamin K2 in nutritional products. We expect that industry interest and confidence in Vitamin K2 will grow now that we can all confirm fortification,” he added.
ChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable “green chemistry” and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. The company has worldwide exclusive patent rights related to pterostilbene. For more information, visit http://www.chromadex.com/ or follow ChromaDex on Twitter @ChromaDex.
About Kappa Bioscience
Kappa Bioscience is the innovative leader and first mover with high purity vitamin K2 as menaquinone-7 (MK-7). Kappa Bioscience is a Norwegian based entity with substantial resources and knowledge about vitamins and vitamin K2 in particular. Kappa Bioscience is currently the only vendor with vitamin K2 as pure MK-7 in various formulations, following a traditional vitamin production process with proprietary and innovative new steps. The company is operating in the US through Xsto Solutions and has its manufacturing in NJ, USA. For further information, visit http://www.kappabio.com
CHROMADEX CONTACTS Investor Inquiries Liviakis Financial Communications, Inc. John M. Liviakis, President 415-389-4670 John@Liviakis.com ChromaDex Contact Jenny Robles Administrative Assistant to the CEO 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 949-419-0288 firstname.lastname@example.org Media Contact Megan Lavine Canale Communications 3033 5th Ave., Suite 400, San Diego, CA 92103 619-849-5388 email@example.com KAPPA BIOSCIENCE CONTACTS Egil Greve Chief Executive Officer +47 95 10 9565 firstname.lastname@example.org Arne Johan Grimsbo VP Strategy & Bus. Dev +47 90 984824 email@example.com
SOURCE ChromaDex Corporation